Raybow PharmaScience (Raybow) is pleased to highlight the use of privileged chiral spiro ligands for asymmetric synthesis with successful application to a number of commercially marketed APls.
BREVARD, N.C., September 21, 2022 /PRNewswire-PRWeb/ -- Raybow PharmaScience (Raybow) is pleased to highlight the use of privileged chiral spiro ligands for asymmetric synthesis with successful application to a number of commercially marketed APls. The key is more than 200 privileged chiral ligands with high enantioselectivity, high turnover number, high stability, ease of handling and readily tunable that Raybow has licensed from a number of leading academic researchers, specifically Professors Qilin Zhou (Nankai University) and Wenjun Tang (Shanghai Institute of Organic Chemistry).
It is important to note that these privileged chiral spiro ligands are free and clear of any Intellectual Property issues and their use will not require any royalty payments from Raybow's clients.
These privileged chiral spiro ligands can be applied to a number of chemical transformations including asymmetric hydrogenation, asymmetric carbonyl reductions, cross-coupling (C-C, C-N, C-B), hydroboration/diboration and nucleophilic addition reactions.
Raybow has applied these privileged chiral ligands to a number of client projects, ranging from Process R&D to metric tonne manufacturing campaigns. Examples include Crizotinib (asymmetric reduction of a carbonyl intermediate; 1 00's of Kg per annum), Ensartinib (asymmetric reduction of a carbonyl intermediate; MT per annum), Rivastigmine (asymmetric reduction of a carbonyl intermediate, 1 00's of Kg per annum) and Aleglitazar (asymmetric hydrogenation; clinical supplies to Phase III). For all these examples more concise and/or higher yielding manufacturing processes with lower costs were developed.
Raybow has further demonstrated the viability of these privileged chiral spiro ligands by their application to a number of other commercially marketed APls at gram to kilo-gram scale. These APls include Montelukast (asymmetric reduction of a ketoester intermediate), Ezetimibe (asymmetric reduction of a ketoacid intermediate), Clopidogrel (asymmetric reduction of a ketoacid intermediate), Dapoxetine (asymmetric reduction of a beta-ketoester intermediate), Empagliflozin (asymmetric reduction of a lactone intermediate) and Silodosin (asymmetric hydrogenation of an olefin intermediate).
We have included 2 examples that showcase our work on our website. View them in our news room.
Raybow will be happy to discuss the potential applicability of these privileged chiral spiro ligands for your chemistry needs. For more information on our services you can visit our website. We showcase some of our R&D capabilities and expertise in Green Chemistry.
Meet us at CPhI Europe (November 1-3, 2022, Frankfurt, Germany) and BioEurope (Oct 24 - 26, 2022, Leipzig, Germany).
Media Contact
Benjamin Hyatt, Raybow PharmaScience, 1-424-317-7475, [email protected]
SOURCE Raybow PharmaScience
Share this article